🆕 ILD (Part II): advanced insights 🫁 Multidisciplinary management 💊 Treatment strategies 📊 Prognosis & monitoring 🧑⚕️ What rheums should know next ⬇️ Download & learn more: https://t.co/XNmbcfqKKF Created by @MithuRheum | For our Rheum to Breathe: ILD Campaign https://t.co/Yhlw3nGsDh

• https://buff.ly/vhnaLoN

Definitions for Interstitial Lung Disease: A Consensusfrom the Fleischner Society https://t.co/2r9oS1Eb9k https://t.co/GqKq5E0bmp

• (PDF) Standardized Clinical Terms and Definitions for Interstitial Lung Disease…

Call to Update the Classification Criteria in Idiopathic Inflammatory Myopathies (IMM), Why? - EULAR/ACR myositis criteria dont cover specific myositis subtypes - Polymyositis is rare - antisynthetase & necrotizing myopathy & Jo1 Dz not well represented - Need to include MSA, https://t.co/P9CEXmEOxl

SMART study - Single vs. Split Dose Methotrexate in RA Split dose weekly, oral methotrexate (MTX) was shown to be superior to single dose MTX in treating active rheumatoid arthritis (RA) patients. https://t.co/K0C63GgHvn https://t.co/FTJ11fpKnB

• SMART study - Single vs. Split Dose Methotrexate in RA | RheumNow

Methyl-prednisolone plus methotrexate-based regime vs prednisone-based standard of care for giant cell arteritis: a propensity score study https://t.co/kmLy6NXFO1

• Methyl-prednisolone plus methotrexate-based regime vs prednisone-based standard…

Optimal glucocorticoid therapy in lupus nephritis 🔓https://t.co/e6SjmOrRpw ➡️This review provides an in-depth analysis of glucocorticoid therapy for lupus nephritis, a severe manifestation of systemic lupus erythematosus that affects up to 51.7% of patients https://t.co/JftCQiFif1

• Optimal glucocorticoid therapy in lupus nephritis
• https://x.com/NDTsocial/status/1968973309745193352/photo/1
• https://x.com/NDTsocial/status/1968973309745193352/photo/1
• https://x.com/NDTsocial/status/1968973309745193352/photo/1
• https://x.com/NDTsocial/status/1968973309745193352/photo/1

🎓 Learning just got smarter. Every week, RheumIQ challenges you with a quick quiz on current rheumatology updates. 💡 Educational 🎯 Evidence-based 🧠 Addictive (in a good way) Try it now and level up your clinical knowledge: https://t.co/mVZhEpn3lo https://t.co/4cMTZXxsUk

• https://buff.ly/iysokek

Study of urinary soluble CD163 levels in 214 SLE pts (129 w/ LN), found urinary CD163 highly correlates w/ UPCR, active vs inactive states, predicts Renal Bx histologic activity (AUC 0.962) & renal dz flares & allows prediction of complete, partial and non-responders https://t.co/HNKAuFDgPG

Controversies in ILD This deep dive into controversies in interstitial lung disease explored complex topics including IPAF, methotrexate, systemic autoimmune rheumatic disease vs. connective tissue disease distinctions, and the evolving role of anti-fibrotic therapy. Panelists: https://t.co/ekP1Gg73yj

GLP-1 drugs cost-effective for knee osteoarthritis and obesity A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents a cost-effective treatment strategy for people with knee https://t.co/pqWDEUgYmI

🆕 Collaboration with @RheumNow 🔵 3-Part Series on #InterstitialLungDisease Part2️⃣: Diagnosis & Subtypes of #ILD 🫁 👩🏻‍⚕️ What to look for on Physical Exam 🧪 Serologic Testing & Diagnostic Workup 🫁 Differentiating ILD Subtypes on Imaging #RheumX #Pulmonology #MedTwitter #MedX https://t.co/X8cJVx2PCV

• https://x.com/MithuRheum/status/1968366583715414330/photo/1

SARD-ILD: Significant diagnostic and treatment delays Should we be screening all our patients with systemic autoimmune rheumatic disease (SARD) for interstitial lung disease? https://t.co/WyccifEHtY https://t.co/S6X5AhZCjz

• SARD-ILD: Significant diagnostic and treatment delays | RheumNow

Infections cause high morbidity & mortality in our immunocompromised rheum patients: vaccinations are essential to keep them healthy. Best time to administer vaccines? 1. Before immunosuppression 2 during periods of dz control 3. >1 vaccines need pt input @LCalabreseDO #CCRW25 https://t.co/oBgXlIk1TY

• https://x.com/KDAO2011/status/1968747552867533017/photo/1